NCT03970798已完成1 期
A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Geometric mean ratio of the major pharmacokinetic parameter (AUC0-t) of the index substrates in combination with or without KW-6356
研究概览
简要总结
The purpose of this study is to evaluate the influence of repeated oral doses of KW-6356 on the pharmacokinetics of index substrates for CYP3A4/5, CYP1A2 and BCRP.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 44 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Individuals having issued written consent to this study at their own discretion
- •Japanese males aged 20 to 44 years at the time of informed consent
- •Body mass index (BMI) of 18.5 to <25.0 at screening
- •Resting pulse rate of 40 to 100 bpm, systolic blood pressure of 90 to 139 mmHg, and diastolic blood pressure of 40 to 89 mmHg when measured in the supine position at screening
排除标准
- •Individuals with any current disease requiring treatment
- •Individuals having drug allergy or its history
- •Individuals having psychiatric disease or its history
- •Positive results for any of the following infection-related items examined at screening: hepatitis B surface (HBs) antigen, HBs antibody, hepatitis B core (HBc) antibody, hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen/antibody, human T-lymphotropic virus (HTLV)-1 antibody, rapid plasma reagin (PRP) test, Treponema pallidum (TP) antibody.
- •Individuals with clinically significant abnormality detected on 12-lead electrocardiogram (ECG) recorded prior to the first dose of index substrate.
- •Individuals categorized as patients listed in the warnings or contraindications section of the package insert of any of the relevant index substrates (see separate protocol annex 6-8)
- •Individuals having used any drug (including over-the-counter [OTC] drugs, topical agents, vitamin preparations, health supplements, and Chinese herbal medicines) within 2 weeks prior to the first dose of index substrate.
- •Individuals having consumed grapefruit (including any food or beverage containing grapefruit) or any food or beverage containing St John's wort within 1 week prior to the first dose of index substrate.
- •Individuals having smoked or used smoking cessation agents (including chewing or eating of nicotine-containing products and application of nicotine patches) within 4 weeks prior to the first dose of index substrate.
- •Individuals having received inpatient treatment or surgery within 12 weeks prior to the first dose of index substrate.
- •Individuals having participated in a clinical study of a pharmaceutical product or a medical device or any equivalent study and used the investigational product or the unapproved medical device within 16 weeks prior to the first dose of index substrate.
- •Individuals having undergone collection of ≥400 mL of blood within 12 weeks prior to the first dose of index substrate or ≥200 mL of blood within 4 weeks prior to the first dose of index substrate (for blood donation or clinical trial, etc.) or pheresis donation (plateletpheresis or plasmapheresis donation) within 2 weeks prior to the first dose of index substrate.
- •Individuals having issued no consent to adoption of any appropriate contraceptive method during a period from day of admission to 12 weeks after the final dose of the study drug. The appropriate contraceptive method is defined as sexual abstinence or use of 2 of the following contraceptive devices: condom, oral contraceptives, intrauterine device, and pessary.
- •Individuals having received KW-6356 before.
- •Other individuals unsuitable for participating in the study in the opinion of the investigator or subinvestigator.
研究组 & 干预措施
KW-6356/Healthy Japanese adult male subjects
Experimental
Period 1: intake of the index substrates at Day 1 (Cohort 1: midazolam, Cohort 2: caffeine + rosuvastatin) followed by Period 2: intake of KW-6356 at Day 4-13, intake of the index substrates at Day 11
干预措施: Midazolam (Drug)
KW-6356/Healthy Japanese adult male subjects
Experimental
Period 1: intake of the index substrates at Day 1 (Cohort 1: midazolam, Cohort 2: caffeine + rosuvastatin) followed by Period 2: intake of KW-6356 at Day 4-13, intake of the index substrates at Day 11
干预措施: Caffeine (Drug)
KW-6356/Healthy Japanese adult male subjects
Experimental
Period 1: intake of the index substrates at Day 1 (Cohort 1: midazolam, Cohort 2: caffeine + rosuvastatin) followed by Period 2: intake of KW-6356 at Day 4-13, intake of the index substrates at Day 11
干预措施: Rosuvastatin (Drug)
KW-6356/Healthy Japanese adult male subjects
Experimental
Period 1: intake of the index substrates at Day 1 (Cohort 1: midazolam, Cohort 2: caffeine + rosuvastatin) followed by Period 2: intake of KW-6356 at Day 4-13, intake of the index substrates at Day 11
干预措施: KW-6356 (Drug)
结局指标
主要结局
Geometric mean ratio of the major pharmacokinetic parameter (AUC0-t) of the index substrates in combination with or without KW-6356
时间窗: Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356
次要结局
- Plasma concentrations of the index substrates(Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356)
- Geometric mean ratio of the major pharmacokinetic parameters (Cmax) of the index substrates in combination with or without KW-6356(Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356)
- Geometric mean ratio of the major pharmacokinetic parameters (AUC0-∞) of the index substrates in combination with or without KW-6356(Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356)
- Pharmacokinetic parameters (tmax) of the index substrates(Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356)
- Pharmacokinetic parameters (CL/F) of the index substrates(Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356)
- Pharmacokinetic parameters (Vz/F) of the index substrates(Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356)
- Pharmacokinetic parameters (t1/2) of the index substrates(Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356)
- Plasma concentrations of KW-6356(Starting around 2 hours before intake of KW-6356 and continued until 24 hours after the last dose of KW-6356)
- Incidence of treatment-emergent adverse events(Starting 24 or 48 hours before intake of the index substrates and continued until 8 days after the last dose of KW-6356)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and DigoxinHealthy ParticipantsNCT05395117AstraZeneca32
已完成
1 期
Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major MetaboliteHepatic ImpairmentNCT04190654Kyowa Kirin, Inc.26
已完成
1 期
HCV-796 and Midazolam Drug Interaction Study in Healthy SubjectsHealthyNCT00410254Wyeth is now a wholly owned subsidiary of Pfizer38
已完成
1 期
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)Locally Advanced or Metastatic Solid TumorsNCT01021748Merck Sharp & Dohme LLC63
已完成
2 期
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing PreparationsParkinson's DiseaseNCT03703570Kyowa Kirin Co., Ltd.502